Sign In
Buy RYTM
$106.19
+4.80 (+4.73%)
At Close: Jun 23, 2026
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D.
08:15am, Friday, 11'th Dec 2020
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di
-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval suppo
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020
04:30pm, Wednesday, 04'th Nov 2020
-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-te
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results
08:00am, Monday, 02'nd Nov 2020
-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global integrated
Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger Largest studies in POMC and LEPR deficiency obesities demonstrate tha
Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
08:00am, Wednesday, 28'th Oct 2020
BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare
